Nezulcitinib clinical trials
Also written TD-0903.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses nezulcitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TD-0903
- 2
Studies by the year they started
3 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses nezulcitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- TD-0903 for ALI Associated With COVID-19CompletedPhase 2Theravance BiopharmaNCT04402866Written as TD-0903How we know
- TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationCompletedPhase 1Theravance BiopharmaNCT05091723Written as Nezulcitinib (TD-0903) Dose AHow we know
- First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19CompletedPhase 1Theravance BiopharmaNCT04350736Written as TD-0903How we know
Codes
What other systems call nezulcitinib · ClinicalTrials.gg INT001723
- MeSH (NLM) C000719753nezulcitinibOne source NLM
- UNII (FDA) CXA4I8AH6ANEZULCITINIBConfirmed FDA, NLM
- NCI Thesaurus C177760NezulcitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719753 | nezulcitinib | One source NLM |
| UNII (FDA) | CXA4I8AH6A | NEZULCITINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C177760 | Nezulcitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.